Clinical handbook of psychotropic drugs
Procyshyn, Ric M. (Ric Michael) 1961- / Bezchlibnyk-Butler, Kalyna Z. 1947- / Jeffries, J. Joel 1939-
23rd edition
2019
454 p.
9780889375611
Anglais
Antidepressants -- Electroconvulsive therapy (ECT) -- Bright light therapy (BLT) -- Repetitive transcranial magnetic stimulation (rTMS) -- Antipsychotics -- Antipsychotic-induced extrapyramidal side effects and their management -- Anxiolytic (Antianxiety) Agents -- Hypnotics/Sedatives -- Mood stabilizers -- Drugs for ADHD -- Drugs for treatment of dementia -- Sex-drive depressants -- Drugs of abuse -- Treatment of substance use disorders -- Unapproved treatments of psychiatric disorders -- Natural health products -- Pharmacogenomic information for common psychotropic drugs -- Glossary -- Drug use in pregnancy and effects on breast milk -- Patient information sheets – Appendix: Neuroscience-Based Nomenclature (NbN) -- Index of drugs.
The Clinical Handbook of Psychotropic Drugs has become a standard reference and working tool for psychiatrists, psychologists, physicians, pharmacists, nurses, and other mental health professionals.
• Independent, unbiased, up-to-date
• Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions…) for a quick overview of treatment options
• Succinct, bulleted information on all classes of medication: on- and off-label indications, (US FDA, Health Canada), recommended dosages, US and Canadian trade names, side effects, interactions, pharmacodynamics, precautions in the young, the elderly, and pregnancy, nursing implications, and much more – all you need to know for each class of drug
• Potential interactions and side effects summarized in comparison charts
• With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek
• Clearly written patient information sheets available for download as printable PDF files
New in this edition
• Antidepressants chapter includes new section on esketamine (Spravato), recently approved for treatment-resistant depression; also updates to antidepressant use in pregnancy and SPARI drug interactions
• Antipsychotics updates include new section on 5-HT2A inverse agonist antipsychotic (pimavanserin, Nuplazid) and comprehensive revision of augmentation strategies
• Pharmacogenomics chapter fully revised with expanded dose adjustment recommendations
• Chart of agents under investigation for treatment of substance use disorders fully revised, new agents include lofexidine (Lucemyra), Kadian, nortriptyline e-cigarettes
• Unapproved treatments chapter with significant updates, including new sections on adrenergic agents in PTSD (doxazosin), antiflammatory agents in depression (pioglitazone, rosiglitazone, statins), and hormones in schizophrenia (raloxifene)
• Expanded treatment options for extrapyramidal side effects include deutetrabenazine and valbenazine
• New formulations and trade names include: Spravato (esketamine), as well as Adzenys ER, Aristada, Austedo, Cotempla XR-ODT, Fanatrex FusePaq, Foquest, Ingrezza, Jornay PM, Mydayis, Nuplazid, Sublocade, Zelapar
This book is a must for everyone who needs an up-to-date, easy-to-use, comprehensive summary of all the most relevant information about psychotropic drugs.
Psychotropes - Guides, manuels, etc.
QV 77.2 C641 2019
N° | Cote | Localisation | |
---|---|---|---|
1 | QV 77.2 C641 2019 | Bibliothèque Rivière-des-Prairies [disponible] |